TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24390146

Group type: EXPERIMENTAL
Intervention: High-dose salsalate therapy for 4 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dose salsalate therapy for 4 weeks (therapeutic salicylate levels, n=31)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dose salsalate therapy for 4 weeks (subtherapeutic salicylate levels)
Number of subjects: 58
Study: 22935844

Group type: EXPERIMENTAL
Intervention: 1 g of intravenous L-carnitine after each dialysis session for 1 year
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 20825715

Group type: EXPERIMENTAL
Intervention: Adjuvant transarterial chemoembolization (TACE) within 2 months after operation
Number of subjects: 2436

Group type: COMPARATOR
Intervention: Control group (resection only)
Number of subjects: 2436
Study: 18203817

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 36
Study: 16988134

Group type: EXPERIMENTAL
Intervention: FVJC
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 12662379

Group type: EXPERIMENTAL
Intervention: N-acetyl cystein (4%) 5 ml t.i.d. for 3 days (AC group, n = 53)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (Placebo group, n = 54)
Number of subjects: 107
Study: 10965386

Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Combination of social support and education
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 363
Study: 8890145

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1556891

Group type: EXPERIMENTAL
Intervention: Thyroplasty type I
Number of subjects: 15
Study: 2869573

Group type: EXPERIMENTAL
Intervention: Beta‐2 agonist terbutaline (0.50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta‐1 agonist prenalterol (less than or equal to 5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31732180

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 30292497

Group type: EXPERIMENTAL
Intervention: Therapeutic Radiographer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Doctor
Number of subjects: 30
Study: 30695570

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Injectable vinorelbine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 4
Study: 25127717

Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (BI)
Number of subjects: 0
Study: 22365802

Group type: EXPERIMENTAL
Intervention: Acute low dose tryptophan depletion (ATD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (T−)
Number of subjects: 26
Study: 20569146

Group type: EXPERIMENTAL
Intervention: Oral PrEP for HIV prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethical concerns regarding the trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General 'science exploitation' discourse
Number of subjects: 0
Study: 18470787

Group type: EXPERIMENTAL
Intervention: Residents with the support of the Varioscope (microscope and loupe glasses with strong illumination and 7x magnification)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Consultant surgeons under standard conditions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Residents with the support of the Varioscope
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High magnification and good lighting
Number of subjects: 40
Study: 16277715

Group type: EXPERIMENTAL
Intervention: 7.2% hypertonic saline hydroxyethyl starch 200/0.5
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mannitol 15%
Number of subjects: 40
Study: 12433732

Group type: EXPERIMENTAL
Intervention: Computer-tailored information
Number of subjects: 0

Group type: COMPARATOR
Intervention: General information
Number of subjects: 0
Study: 10730531

Group type: EXPERIMENTAL
Intervention: 4 grams of tuna fish oil
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 8602477

Group type: EXPERIMENTAL
Intervention: Intervention group (treatment for subacute low back pain)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 103
Study: 1974628

Group type: EXPERIMENTAL
Intervention: Ribavirin 800 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ribavirin 600 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 7277290

Group type: EXPERIMENTAL
Intervention: Flow sheet design of medical record
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical record (implied control)
Number of subjects: 0
Study: 31559410

Group type: EXPERIMENTAL
Intervention: Reduced red and processed meat consumption
Number of subjects: 37
Study: 28952139

Group type: EXPERIMENTAL
Intervention: Magill forceps
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vascular forceps with tube exchanger
Number of subjects: 60
Study: 25307883

Group type: EXPERIMENTAL
Intervention: Indwelling urinary catheter
Number of subjects: 314

Group type: COMPARATOR
Intervention: No urinary catheter
Number of subjects: 314
Study: 24322879

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei NCC 2461 (ST11)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22958738

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced CNI exposure
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard CNI-therapy
Number of subjects: 78
Study: 19203529

Group type: EXPERIMENTAL
Intervention: Hutex omeprazole (20 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Yuhan Losec (20 mg)
Number of subjects: 24
Study: 17970234

Group type: EXPERIMENTAL
Intervention: Intravenous rasburicase at a dose of 0.02 mg/kg/day for varying durations based on serum uric acid levels (3 days for 8-10 mg/dl, 5 days for 10-15 mg/dl, 7 days for >15 mg/dl)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group receiving allopurinol (not explicitly detailed in the abstract)
Number of subjects: 43
Study: 16279468

Group type: EXPERIMENTAL
Intervention: Diffuse optical correlation methods; hand-held optical probe manually scanned over the tumor-bearing breast.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (healthy tissue); no specific intervention mentioned.
Number of subjects: 0
Study: 12113396

Group type: EXPERIMENTAL
Intervention: English SF-36 version
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Chinese SF-36 version
Number of subjects: 168

Group type: COMPARATOR
Intervention: Both versions
Number of subjects: 168
Study: 10471017

Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no TT)
Number of subjects: 41
Study: 7774443

Group type: EXPERIMENTAL
Intervention: Combined operative resection and immuno-chemotherapy (OIC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined operative resection and immunotherapy (OI)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Combined operative resection and chemotherapy (OC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Resection only (OP)
Number of subjects: 121
Study: 2328258

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6158263

Group type: EXPERIMENTAL
Intervention: N-acetylprocainamide (NAPA)
Number of subjects: 23
Study: 30963446

Group type: EXPERIMENTAL
Intervention: Risk of Bias assessment tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpretations of judgment in the RoB tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors contributing to high risk of bias
Number of subjects: 0
Study: 28032810

Group type: EXPERIMENTAL
Intervention: Active Classrooms intervention (movement integrated into academic lessons)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Delayed-treatment control group
Number of subjects: 248
Study: 26885107

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) + Mycophenolate mofetil (MMF), n=42
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX), n=40
Number of subjects: 82
Study: 23280073

Group type: EXPERIMENTAL
Intervention: Citrate-containing dialysate (Cit)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard tinzaparin hemodialysis (tinzaparin-HD)
Number of subjects: 23
Study: 20872758

Group type: EXPERIMENTAL
Intervention: Readiness and Motivation Therapy (RMT)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 181
Study: 19576320

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet regimen (aspirin plus clopidogrel plus cilostazol)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Dual antiplatelet regimen (aspirin plus clopidogrel)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: CYP2C19*3A allele presence
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: CYP2C19*3
Number of subjects: 450
Study: 17313501

Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 3266

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status
Number of subjects: 3266

Group type: EXPERIMENTAL
Intervention: Frequent symptoms
Number of subjects: 3266

Group type: EXPERIMENTAL
Intervention: Severe symptoms
Number of subjects: 3266

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 3266
Study: 14751102

Group type: EXPERIMENTAL
Intervention: Modified Transthecal Digital Block (MTDB)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional Digital Block (TDB)
Number of subjects: 25
Study: 10720518

Group type: EXPERIMENTAL
Intervention: Thalidomide therapy
Number of subjects: 0
Study: 9167106

Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Diabetes Specialist Nurse Education (DSNE)
Number of subjects: 26
Study: 15374367

Group type: EXPERIMENTAL
Intervention: Idebenone 45 mg twice daily p.o.
Number of subjects: 79

Group type: COMPARATOR
Intervention: Oxiracetam 800 mg twice daily p.o.
Number of subjects: 79
Study: 6338893

Group type: EXPERIMENTAL
Intervention: 5% dextrose solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hartmann's solution
Number of subjects: 0
Study: 31778196

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 4154

Group type: COMPARATOR
Intervention: Rifaximin
Number of subjects: 4154

Group type: EXPERIMENTAL
Intervention: Single-dose antibiotic therapy
Number of subjects: 4154

Group type: EXPERIMENTAL
Intervention: Prevent TD clinical trial
Number of subjects: 4154
Study: 30134944

Group type: EXPERIMENTAL
Intervention: Surgical treatment with posterior C1-C2 fusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-surgical treatment with a rigid cervical collar for 12 weeks
Number of subjects: 50
Study: 26970335

Group type: EXPERIMENTAL
Intervention: 2.6 g omega‐3 LCPUFA supplementation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo of 2.7 g soya bean oil
Number of subjects: 95
Study: 26118632

Group type: EXPERIMENTAL
Intervention: HBV‐pulsed DCs plus entecavir
Number of subjects: 80

Group type: COMPARATOR
Intervention: HBV‐pulsed DCs only
Number of subjects: 80

Group type: COMPARATOR
Intervention: entecavir only
Number of subjects: 80

Group type: COMPARATOR
Intervention: untreated control group
Number of subjects: 80
Study: 21693549

Group type: EXPERIMENTAL
Intervention: Pregabalin 300-600 mg/day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 20608895

Group type: EXPERIMENTAL
Intervention: Strict control of morning home systolic blood pressure (SBP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mild control of morning home systolic blood pressure (SBP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 80
Study: 18355335

Group type: EXPERIMENTAL
Intervention: Milk-free diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reexposure to milk
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 12
Study: 15781528

Group type: EXPERIMENTAL
Intervention: IV fluid administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluid types and administration strategies
Number of subjects: 0
Study: 15255625

Group type: EXPERIMENTAL
Intervention: Yoga practitioners (50 subjects)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (50 subjects)
Number of subjects: 100
Study: 10682127

Group type: EXPERIMENTAL
Intervention: Zalcitabine 0.75 mg every 8 hours
Number of subjects: 940

Group type: COMPARATOR
Intervention: Saquinavir 600 mg every 8 hours
Number of subjects: 940

Group type: COMPARATOR
Intervention: Combination zalcitabine 0.75 mg plus saquinavir 600 mg every 8 hours
Number of subjects: 940
Study: 8923548

Group type: EXPERIMENTAL
Intervention: Selective amputations of the angle components in the wings-in form of the Müller-Lyer illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective amputations of the angle components in the wings-out form of the Müller-Lyer illusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method of paired comparisons and method of reproduction
Number of subjects: 0
Study: 1747216

Group type: EXPERIMENTAL
Intervention: Quinapril (5 mg oral twice daily, titrated to 20 mg twice daily)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Captopril (25 mg oral twice daily, titrated to 100 mg twice daily)
Number of subjects: 97
Study: 402697

Group type: EXPERIMENTAL
Intervention: b.i.d. dosage schedule of 500 mg twice daily
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: t.i.d. dosage schedule of 250 mg three times daily
Number of subjects: 327
Study: 31708422

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg bolus before incision, followed by 0.5 mg/kg/h infusion until end of surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 80
Study: 31161498

Group type: EXPERIMENTAL
Intervention: Pharmacist's intervention (PharmaFit Protocol)
Number of subjects: 44
Study: 28671307

Group type: EXPERIMENTAL
Intervention: Insulin iontophoresis in IS groups (ABIS and SCIS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acetylcholine iontophoresis in SCI subgroups
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Net insulin response (NetIns) in IS cohorts (ABIS and SCIS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo iontophoresis
Number of subjects: 62
Study: 25837184

Group type: EXPERIMENTAL
Intervention: Zolpidem (multimodal analgesia + zolpidem)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (multimodal analgesia)
Number of subjects: 78
Study: 23256927

Group type: EXPERIMENTAL
Intervention: Ownership of alcohol-branded merchandise (ABM)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Exposure to alcohol brands in movies
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Peer drinking and sensation seeking
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Marketing-specific cognitions (drinker identity and favorite brand to drink)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: 30-day binge drinking
Number of subjects: 1734
Study: 21473979

Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia/fibrillation (VT/VF)
Number of subjects: 5259

Group type: COMPARATOR
Intervention: No VT/VF
Number of subjects: 5259

Group type: EXPERIMENTAL
Intervention: Early and late VT/VF
Number of subjects: 5259
Study: 19953902

Group type: EXPERIMENTAL
Intervention: Interferon-beta
Number of subjects: 3115
Study: 23439596

Group type: EXPERIMENTAL
Intervention: L‐NMMA (NOS inhibitor)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15987284

Group type: EXPERIMENTAL
Intervention: Tacalcitol ointment (4 microg/g) applied once daily for 2 months
Number of subjects: 556
Study: 12962951

Group type: EXPERIMENTAL
Intervention: Tolterodine extended release 4 mg once daily
Number of subjects: 772

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 772
Study: 10543293

Group type: EXPERIMENTAL
Intervention: Home i.v. antibiotic treatment (HIVAT, 14 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled amiloride (14 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (14 days)
Number of subjects: 10
Study: 7818568

Group type: EXPERIMENTAL
Intervention: Tenidap (120 mg/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Piroxicam (20 mg/day)
Number of subjects: 49
Study: 2678231

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amidotrizoate
Number of subjects: 50
Study: 713434

Group type: EXPERIMENTAL
Intervention: Tinofedrine (0.12‐‐0.17 mg/kg bodyweight)
Number of subjects: 45
Study: 30175433

Group type: EXPERIMENTAL
Intervention: Hamilton‐T1 mechanical ventilator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self‐inflating resuscitator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Flow‐inflating resuscitator
Number of subjects: 30

Group type: COMPARATOR
Intervention: LTV 1200 mechanical ventilator
Number of subjects: 30
Study: 27622693

Group type: EXPERIMENTAL
Intervention: Force-limiting instrument
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard instrument
Number of subjects: 12
Study: 24287284

Group type: EXPERIMENTAL
Intervention: 1.8 g/day esterified plant sterols and stanols
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22396408

Group type: EXPERIMENTAL
Intervention: Prior probability manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potential payoff manipulation
Number of subjects: 0
Study: 20350253

Group type: EXPERIMENTAL
Intervention: Xuezhikang (0.6 g twice daily)
Number of subjects: 2704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2704
Study: 18304665

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmedicated AD/HD children (control group)
Number of subjects: 0
Study: 16088423

Group type: EXPERIMENTAL
Intervention: Postoperative hospital stay of 2 days
Number of subjects: 238

Group type: COMPARATOR
Intervention: Postoperative hospital stay longer than 2 days (Control)
Number of subjects: 238
Study: 12184518

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (PHGG) 5 g/day
Number of subjects: 188

Group type: COMPARATOR
Intervention: Wheat bran 30 g/day
Number of subjects: 188
Study: 10090192

Group type: EXPERIMENTAL
Intervention: Modified Sharp score (0-448 scale)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Modified Larsen score (0-200 scale)
Number of subjects: 52
Study: 7788147

Group type: EXPERIMENTAL
Intervention: CDP571 (10 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CDP571 (1.0 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CDP571 (0.1 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2193996

Group type: EXPERIMENTAL
Intervention: Informed group (received patient education about drug side effects)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Uninformed group (no information about drug side effects)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (compliance with therapy)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (results of treatment)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Informed group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Uninformed group
Number of subjects: 98
Study: 84951

Group type: EXPERIMENTAL
Intervention: Antipyrine (phenazone) treatment of mothers from the 38th week of pregnancy
Number of subjects: 48
Study: 31268524

Group type: EXPERIMENTAL
Intervention: BrightBrainer Virtual Rehabilitation (BBVR) system
Number of subjects: 21
Study: 31298333

Group type: EXPERIMENTAL
Intervention: Knockdown of AB073614
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overexpression of AB073614
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expression of AB073614 in NSCLC tissues
Number of subjects: 0
Study: 28922968

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (2400 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25385207

Group type: EXPERIMENTAL
Intervention: Teamwork approaches with incremental delegation of non-clinical tasks away from physicians.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Team 'huddles' guided by pre-visit planning.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Inclusion of nurse care managers in care plan design and execution.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Desire for on-site teamwork training for key team members.
Number of subjects: 63
Study: 23815692

Group type: EXPERIMENTAL
Intervention: Lecture plus live demonstration
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 26
Study: 21387175

Group type: EXPERIMENTAL
Intervention: DHS (dynamic hip system screw)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: DHS blade (dynamic hip system blade)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Gamma3 Trochanteric Nail
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: PFNA (proximal femoral nail antirotation)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Screw group (DHS and Gamma nail)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Blade group (DHS blade and PFNA)
Number of subjects: 335
Study: 19424709

Group type: EXPERIMENTAL
Intervention: Minimally invasive approach (modification of the Hardinge‐approach)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Classical lateral approach
Number of subjects: 51
Study: 16751162

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 5 microg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intrathecal morphine)
Number of subjects: 24
Study: 15244198

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis C patients with steatosis (n=23)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Chronic hepatitis C patients without steatosis (n=8)
Number of subjects: 31